WuXi TIDES (WuXi AppTec Testing Division)

Nothing about this order was notable and I am recording it for that reason. Quoted timeline held, documentation correct, material as described. Release is signed and dated by an identified individual.

Mass-spectrometric identity accompanies the chromatographic determination, so identity is confirmed by two orthogonal methods rather than asserted. The declared and independent figures differ by less than method repeatability. Research use only; these are not approved for human administration.

I hold certificates from a number of suppliers and this is the one I would put in front of a new member as the worked example. Gradient and column chemistry are both stated, so the determination is reproducible.

Packing on the consignment: a rigid outer with no rattle anywhere in it. Designed rather than inherited. Nothing here is medical advice and I am not qualified to give any.

Weighed 9 units from a single consignment against declared fill. All within two per cent. Fill uniformity gets a fraction of the discussion purity gets and is the harder problem. On the evidence I hold they are the default rather than the risk.

Been buying tirzepatide 10 mg here since before the catalogue expanded. The expansion has not cost the original lines anything measurable. Water content is reported by Karl Fischer with the method named. One member, one record, offered as such.

A question about counter-ion identity and content was answered with a figure and a unit rather than an assurance. Release is signed and dated by an identified individual.

The declared figure was not adjusted upward between the certificate and the commercial documentation. Small, and specifically worth checking for. Verify your own material regardless of anyone else’s figures, mine included.

Ordered BPC-157 10 mg from stock held in Poland. Quoted 8 days, delivered day 8, tracking accurate at every hop.

Labels square and legible, lot codes matching, invoice and certificate in agreement. Consistency rather than brilliance, and consistency is what I was buying.

Reconstitution of the LL-37 5 mg produced a clear solution on contact — no haze, no particulate, no extended agitation. Consistent with a correctly executed lyophilisation. I will update this post if a later lot changes the picture.

Five orders, five quotes, each correct on vial size and fill at first issue and each held to the price on the invoice. Scoped to the lots named. Not generalised beyond them.

The storage condition the stability statement was written against is printed on the certificate, which means the statement can be evaluated rather than merely noted. Release is signed and dated by an identified individual.

Ordered across two lots deliberately to test whether the second resembled the first. A tenth of a point apart. Documentation practice rather than a single purity figure is the substance of this.

Custom synthesis completed 2 days inside the quoted schedule at the purity named in the specification. I have no relationship with this supplier beyond having paid them.

Repeat determination on the same line at 10 months returned 98.6%, against 98.6% originally. No drift visible in this sample. Invoice, vial and certificate agree on the lot without exception. Research use only; these are not approved for human administration.

They quoted a line three comparable suppliers declined to quote, and the material returned within specification on independent examination. Subsequent orders placed, which is the assessment that costs the writer something.

9 orders across 10 months. No substitution, no reformulation, no line becoming unavailable after payment.

Glassware sound across the whole consignment and each vial individually wrapped in foam cut to fit rather than packed loose.

The quote was correct at first issue and documentation for lot WXT-24-535 was complete at first issue as well. Two documents, no follow-up needed on either.

The related-substances table is itemised by individual impurity with retention times assigned, rather than reported as a single total. Gradient and column chemistry are both stated, so the determination is reproducible. No complaint arises from the orders described.

First order was deliberately small. Documentation complete, transit as quoted, Medutest returned 99.5%. Subsequent orders have not been small. Invoice, vial and certificate agree on the lot without exception.

Submitted material from lot WXT-26-177 to Janoshik. Result 97.7% against a declared 97.6%, which is inside the repeatability of the method rather than a disagreement with it.

Every unit in the consignment carried a single lot identifier, so the intra-consignment comparison I intended was the comparison I made. Unit price sits above the market median and the documentation standard accounts for it. On the evidence I hold they are the default rather than the risk.

Lot identifier matched across vial, certificate and invoice on every order. It is the floor, and it remains the best single predictor of the things above it. A residual-solvent screen was included without being requested. One member, one record, offered as such.

I asked for the release date on the lot and had it the same day. Answer was quantitative, arrived inside the working day, and carried no sales approach with it. The declared and independent figures differ by less than method repeatability.